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a b s t r a c t
The role of amygdaloid glutamatergic receptors (GluRs) in maintenance of the sensory versus emo-
tional component of neuropathic pain was studied by assessing monoﬁlament-induced limb withdrawal
response (sensorypain) andaversiveplace-conditioningbehavior (emotional pain) followingamygdaloid
administration of various glutamatergic compounds in nerve-injured animals. The results indicate that
endogenous activation of amygdaloid group Imetabotropic GluRs,mGluR1 andmGluR5, and theNMDA-R
contributes to maintenance of sensory and emotional components of neuropathic pain. The predominant
effect by amygdaloid group I mGluRs was facilitation of emotional-like pain behavior.
© 2010 Elsevier B.V. All rights reserved.
The amygdala has an important role in emotions [14] and
contributes to processing and modulation of pain [9]. Recent stud-
ies indicate that peripheral nerve injury that is associated with
chronic pain induces neural plasticity in the amygdala as shown
by increased postsynaptic currents evoked by ascending inputs
[5] and generation of new amygdala neurons [4]. Additionally,
glutamatergic stimulation of the amygdala in nerve-injured ani-
mals increases the discharge rate of pronociceptive medullary
neurons [1], decreases the discharge rate of antinociceptive pon-
tine neurons [15], and promotes emotional-like pain behavior [1].
These ﬁndings support the hypothesis that neural plasticity in
the amygdala that involves a change in the function of amyg-
daloid glutamate receptors plays a role in maintenance of chronic
neuropathic pain. However, the contribution of various subtypes
of amygdaloid glutamate receptors to the sensory versus emo-
tional (affective-motivational) component of neuropathic pain is
still poorly known. In the present study, we investigated the roles
of amygdaloid group I metabotropic glutamate receptors (mGluRs)
and NMDA-Rs in endogenous regulation of mechanically induced
limb withdrawal response (an index for the sensory component of
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pain) and aversive place-conditioning behavior (an index for the
emotional component of pain) in animals with a peripheral neu-
ropathy.
The experiments were performed in adult, male Hanover-
Wistar rats weighing 180–190g at the beginning of the experiment
(Harlan, Horst, The Netherlands). The experimental protocol was
accepted by the Institutional Ethics Committee and the experi-
ments were performed according to the guidelines of European
CommunitiesCouncilDirectiveof24November1986 (86/609/EEC).
All efforts were made to minimize animal suffering and to use
only the number of animals necessary to produce reliable scientiﬁc
data.
The unilateral axotomy and ligation of the tibial and common
peroneal nerves were performed under pentobarbitone anesthesia
(50mg/kg i.p.) as described in detail earlier [2,3]. After the surgery,
the animals were allowed to recover before the actual testing that
was performed either 1 or 8 weeks after the operation. Devel-
opment of hypersensitivity was veriﬁed behaviorally in animals
habituated to the experimental conditions 1–2h daily for 2–3 days.
Only animals that developed tactile allodynia-like symptoms (the
limb withdrawal threshold to monoﬁlament stimulation ≤1g) in
the sural nerve area of the injured limb were considered further
in this study. For control purpose, a group of animals were sham-
operated; in the sham group, the operation was identical, except
that the nerves were not ligated. Sham operation as well as nerve
ligation was performed in the left side.
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The animals were installed with stainless steel guide cannu-
lae (26 gauge; PlasticsOne, Roanoke, VA) for drug administration
into the amygdala ipsi- and contralateral to the spared nerve injury
under pentobarbitone anesthesia (50mg/kg i.p.) at least one week
before behavioral testing. For placement of the guide cannulae,
the skull was exposed and holes drilled for their placement. The
desired injection sites were in the central nucleus of the amyg-
dala (CeA): 7.12mm anterior from the ear bar, 4.00mm lateral (left
and right) from the midline, and 8.00mm ventral from the dura
mater [11]. The tips of the guide cannulae were positioned 2mm
above the desired injection site. The guide cannulaewere ﬁxed into
the skull using dental screws and dental cement. Dummy cannu-
lae were placed in the guide cannulae, when the animal was not
tested.
Drugs or saline control were microinjected into the amygdala
through a 33-gauge stainless steel injection cannula (PlasticsOne)
inserted through and protruding 2mm beyond the tip of the guide
cannula. The microinjection was made using a 10l Hamilton
syringe (Hamilton Company, Bonaduz, Switzerland) that was con-
nected to the injection cannula by polyethylene (PE-10) tubing. The
volume of injection was 0.5l. At this volume, the spread of the
injected drugs within the brain was at least 1mm [8]. The efﬁcacy
of injectionwasmonitoredbywatching themovementof a small air
bubble through the tubing. The injection lasted 30 s and the injec-
tion cannula was left in place for an additional 30 s to minimize
ﬂow of the drug solution back up the injector track.
Rate of the limb withdrawal response to repetitive monoﬁla-
ment stimulation of the sural nerve area of the injured limb at
the force of 1.4 g (North Coast Medical, Inc., Morgan Hill, CA) was
used as an index for the sensory component of pain. The monoﬁl-
ament stimulation was performed ﬁve times at about 2 s intervals.
Response rate of 100% indicates that the animal withdrew the limb
at every stimulus presentation, whereas response rate of 0% indi-
cates that animal did not withdraw its limb at any of the stimulus
presentations. Place-avoidance test adapted from that described
earlier [6] was used to obtain a measure of emotional pain induced
by mechanical stimulation of the injured hind paw. Before testing,
the animals were habituated to the test conditions by spending
1–2h daily for 2 days in the test box. In the actual testing, the rat
wasplacedwithin aPlexiglas chamber (60 cm×30 cm×30 cm;one
half of which was painted black on the external surface) placed
upon an elevated metal grid. The rats were placed over the midline
of the chamber and stimulation of the plantar surface of the hind
paw was performed with a 60g monoﬁlament (North Coast Medi-
cal, Inc.) once every 15 s for 15min. When residing within the dark
side of the chamber the injured or sham-operated hind paw was
stimulated. Conversely, the non-operatedhindpawwas stimulated
when residing within the light side of the chamber. Throughout
the 15min test period rats were allowed unrestricted movement
throughout the chamber. The percent time spent in the light side
of the chamber during the 15min observation period was deter-
mined in each condition for each animal. It is assumed that the
more aversive the mechanical stimulation of the hind paw, the
more the animal spends time in the light side of the chamber;
i.e., the place-avoidance test is considered to assess emotional pain
behavior [6].
(S)-3,5-dihydroxyphenylglycine (DHPG; an mGluR1/5 ago-
nist), (RS)-2-chloro-5-hydroxy (CHPG; an mGluR5 agonist),
6-methyl-2-(phenylethynyl)pyridine (MPEP; an mGluR5 antag-
onist), (+)-MK-801 hydrogen maleate (MK-801; an NMDA-R
antagonist) were purchased from Sigma (St. Louis, MO) and
7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl
ester (CPCCOEt; an mGluR1 antagonist) was purchased from Tocris
(Bristol, UK). Physiological saline was used for control injections.
Drugs were dissolved in saline, except for CPCCOEt that was dis-
solved in DMSO. In the choice of drug doses and time points for
testing, previously published results [1,13] and preliminary exper-
iments were taken into account.
In the bilateral treatment groups, the drug conditions
were saline, DMSO, DHPG at the dose of 10nmol/amygdala
(20nmol/animal), MPEP at the dose of 50nmol/amygdala
(100nmol/animal), MK-801 at the dose of 3nmol/amygdala
(6nmol/animal), and CPCCOEt at the dose of 20nmol or
40nmol/amygdala (40nmol or 80nmol/animal), respectively.
In the unilateral treatment groups, drug conditions were saline,
20nmol of CPCCOEt, or 40nmol of CPCCOEt either ipsi- or con-
tralateral to nerve injury. In all experimental conditions, drugs
were administered into the amygdala 5min before the start of
the place-avoidance test. Duration of the place-avoidance test
was 15min; i.e., place-avoidance test was performed 5–20min
after amygdaloid administration of the studied compound. Limb
withdrawal response to repetitive stimulation of the operated paw
was assessed immediately after the end of the place-avoidance
test; i.e., limb withdrawal test was performed 20min after amyg-
daloid injection of the studied compounds. In each experimental
group, each drug condition was assessed in a separate day, 1–2
weeks following nerve injury. Each animal participated in 3–4 drug
testing sessions. The interval between different drug conditions in
one animal was at least 2 days. The order of testing different drug
conditions was varied within the groups to avoid serial effects.
Data are presented as mean± S.E.M. One- or two-way ANOVA
followed by Tukey’s test, t-test with a Bonferroni correction for
multiple comparisons, or unpaired t-test (differences between two
experimental groups) were used in statistical analysis of the data.
P<0.05 was considered to represent a signiﬁcant difference.
Nerve injury inducedmarkedchanges in sensoryandemotional-
like pain behaviors as indicated by the limb withdrawal
response and aversive place-conditioning tests, respectively. In
sham-operated control animals (n=6), repetitive monoﬁlament
stimulation of the sural nerve area at the force of 1.4 g produced
no responses (not shown), whereas in nerve-injured animals, the
limb withdrawal rate following bilateral injection of saline was
92±5% (n=5; Fig. 1A). In the aversive place-conditioning test,
sham-operated animals spent only 5±1% (n=6) of the test time in
the light compartment (not shown), whereas saline-treated nerve-
injured animals spent 40±8% (n=5) of the test time in the light
compartment (Fig. 1B). A separate control experiment in nerve-
injured animals (n=5) indicated that the limbwithdrawal response
to repetitive presentation of a monoﬁlament at a force of 1.4 g was
of the same magnitude independent whether the limb withdrawal
test was performed before or after the aversive place-avoidance
test (t8 =0.8, t-test; not shown). Due to lack of on-going sensory
or emotional-like pain behavior in sham-operated animals, pain-
modulatory inﬂuence by endogenous activation of amygdaloid
glutamatergic receptors was studied with speciﬁc receptor antag-
onists only in nerve-injured animals.
Bilateral administration of DHPG, an mGluR1/5 agonist into the
CeA(20nmol/animal), failed to inﬂuence limbwithdrawal response
(Fig. 1A); due to a high baseline value, however, it may not be pos-
sible to exclude a DHPG-induced increase in the limb withdrawal
response. Bilateral administration of DHPG (20nmol/animal)
increased emotional-like pain behavior (Fig. 1B). Bilateral adminis-
tration of CPCCOEt, anmGluR1 antagonist, produced a dose-related
(40–80nmol/animal) decrease in the limb withdrawal response
(F2,10 = 31.2, P<0.0001; Fig. 1C) and emotional-like pain behavior
(F2,10 = 7.4, P<0.02; Fig. 1D); at a lower dose (40nmol/animal), CPC-
COEt produced a signiﬁcant reduction only in the emotional-like
pain behavior. Vehicle for CPCCOEt was DMSO. When compared
with saline, DMSO alone (n=4) did not inﬂuence the limb with-
drawal response (t7 =0.45; not shown) or emotional-like pain
behavior (t7 =0.27; not shown). Bilateral administration of MPEP,
an mGluR5 antagonist, failed to reduce limb withdrawal responses
Author's personal copy
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Fig. 1. An index for the sensory component of pain, hind limb withdrawal response elicited by repetitive mechanical stimulation of the nerve-injured paw (left column)
and an index for the emotional component of pain, aversive place-conditioning behavior (right column) following bilateral amygdaloid injection of saline (Sal) or various
glutamatergic compounds. The doses/animal of the injected glutamatergic compounds are shown in theX-axis. A decrease in the limbwithdrawal response rate (left columns)
and time spent in the light compartment (right columns) are considered to indicate a decrease in sensory and emotional-like pain, respectively. DHPG is an mGluR1/5 agonist,
CPCCOEt an mGluR1 antagonist, MPEP an mGluR5 antagonist, and MK-801 an NMDA-R antagonist. Error bars represent S.E.M. (n=4–8). *P<0.05, **P<0.01, ***P<0.005 (in C
and D, Tukey’s test, in other graphs, t-test; reference: the corresponding Sal-group).
at a dose (100nmol/animal; Fig. 1E) that was enough to pro-
duce a signiﬁcant attenuation of the emotional-like pain behavior
(Fig. 1F). Bilateral administration of MK-801, an NMDA-R antag-
onist (6nmol/animal), produced a signiﬁcant attenuation of both
the limbwithdrawal response (Fig. 1G) and the emotional-like pain
behavior (Fig. 1H).
CPCCOEt (20–40nmol/side) or saline was administered uni-
laterally to study pain-modulatory roles of the CeA ipsi- versus
contralateral to nerve injury. Limb withdrawal response was
reduced in a dose-related fashion by unilateral injections of CPC-
COEt (F2,37 = 32,7, P<0.0001; Fig. 2A). The suppression of the
limb withdrawal response was stronger following amygdaloid
administration of CPCCOEt contra- than ipsilateral to nerve injury
(F1,37 = 7.55, P<0.01), independent of the dose (F2,37 = 2.65). Unilat-
eral administrationofCPCCOEt suppressedalsoemotional-likepain
behavior in a dose-related fashion (F2,37 = 8.5, P<0.001; Fig. 2B).
Suppression of emotional-like pain behavior was of the same
magnitude following unilateral injection of CPCCOEt ipsi- as con-
tralateral to nerve injury (F1,37 = 0.23). At the currently used doses,
the studied compounds failed to produce any obvious side-effects.
Histological analysis indicated that amygdaloid injection siteswere
in or adjacent to the CeA (Fig. 3).
The present results indicate that amygdaloid group I and NMDA
receptors contribute tomaintenance of sensory and emotional-like
pain in peripheral neuropathy. The ﬁnding that group I mGluR
antagonists attenuated emotional-like pain behavior at a lower
dose than limb withdrawal responses suggests that amygdaloid
group I mGluRs may have a more important role in promotion
of emotional-like pain than sensory aspects of pain. This ﬁnding
also suggests that the modulation of emotional-like pain behav-
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Fig. 2. Hind limb withdrawal response elicited by mechanical stimulation of the
nerve-injured paw (A) and aversive place-conditioning behavior (B) following uni-
lateral amygdaloid injection of saline or CPCCOEt (an mGluR1 antagonist) at the
dose of 20 or 40nmol/animal. Ipsi = amygdaloid injection ipsilateral to nerve injury,
contra = amygdaloid injection contralateral to nerve injury. Error bars represent
S.E.M. (n=4–9). *P<0.05 (t-test with a Bonferroni correction; comparison between
corresponding values in the ipsi- versus contra-group).
ior by amygdaloid administration of compounds acting on group I
mGluRs is predominantly a direct effect onmechanismsunderlying
emotional pain rather than indirect effect due to enhancement of
pain-related sensory signals.
A previous electrophysiological study demonstrated plasticity
of synaptic inputs from the parabrachial nucleus to the CeA, and
this synaptic plasticity was independent of the NMDA receptor in
peripheral neuropathy [5], unlike in inﬂammatory conditions [7]. In
thepresent study, anNMDA-Rantagonist in theCeA facilitatedboth
sensory andemotional-likepainbehavior innerve-injured animals.
A possible explanation for these ﬁndings is that the amygdaloid
NMDA-R plays a role in maintenance of neuropathic symptoms
by facilitating inputs from the basolateral amygdala or synaptic
signaling between interneurons within the CeA rather than facili-
tating the ascending spino-parabrachial-amygdala input. It should
be noted that nerve injury may induce pathophysiological changes
also in the function of various other amygdaloid neurotransmitter
receptors, suchasGABAA-R [12] thatmaycontribute toneuropathic
symptoms.
Suppressionof spinalwithdrawal responsewas slightly stronger
following administration of the mGluR1 antagonist into the CeA
contra- than ipsilateral to nerve injury, while the suppression
of emotional-like pain was of the same magnitude following
ipsi- as contralateral administration. This difference, together with
Fig. 3. Injection sites in the amygdala. Upper graph shows an example of a lesion
induced by the injection needle in a Nissl-stained coronal section. Triangles in lower
schematic diagrams represent injections sites (each triangle represents 1–3 sites).
BLA, basolateral amygdaloid nucleus; CeA, central amygdaloid nucleus; ic, internal
capsule; and *, tip of the cannula.
the differential dose-dependence in the modulation of sensory
and emotional-like pain by group I mGluR antagonists, sup-
ports the hypothesis that amygdaloid mechanisms promoting
sensory and emotional-like pain in neuropathy are, at least partly,
different.
While earlier studies have shown that under physiological con-
ditions the amygdala has a role in induction of analgesia [for review
see Ref. [9]], the present results add to the accumulating evidence
indicating that under inﬂammatory [7,10] and neuropathic [1,5,15]
conditions amygdaloid glutamatergic receptorsmay promote pain.
Endogenous activation of the amygdaloid group I mGluRs may
be of particular importance for the promotion of emotional-like
neuropathic pain as revealed by the predominant suppression of
the aversive place-conditioning behavior following amygdaloid
administration of group I mGluR antagonists in nerve-injured ani-
mals.
Acknowledgements
This study was supported by the Academy of Finland, Helsinki,
Finland, the Sigrid Jusélius Foundation,Helsinki, Finland, theCenter
for InternationalMobility (CIMO), Helsinki, Finland, the Portuguese
Foundation for Science and Technology, Lisbon, Portugal, and the
Gulbenkian Foundation, Lisbon, Portugal.
Author's personal copy
178 O.B. Ansah et al. / Behavioural Brain Research 209 (2010) 174–178
References
[1] Ansah OB, Gonc¸alves L, Almeida A, Pertovaara A. Enhanced pronociception by
amygdaloid group I metabotropic glutamate receptors in nerve-injured ani-
mals. Exp Neurol 2009;216:66–74.
[2] Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent
peripheral neuropathic pain. Pain 2000;87:149–58.
[3] Gonc¸alves L,AlmeidaA, PertovaaraA. Pronociceptive changes in responseprop-
erties of rostroventromedial medullary neurons in a rat model of peripheral
neuropathy. Eur J Neurosci 2007;26:2188–95.
[4] Gonc¸alves L, Silva R, Pinto-Ribeiro F, Pêgo JM, Bessa JM, Pertovaara A, et al.
Neuropathic pain is associated with depressive behaviour and induces neuro-
plasticity in the amygdala of the rat. Exp Neurol 2008;213:48–56.
[5] Ikeda R, Takahashi Y, Inoue K, Kato F. NMDA receptor-independent synaptic
plasticity in the central amygdala in the rat model of neuropathic pain. Pain
2007;127:161–72.
[6] LaBudaCJ, Fuchs PN.Abehavioral test paradigmtomeasure the aversivequality
of inﬂammatory and neuropathic pain in rats. Exp Neurol 2000;163:490–4.
[7] Li W, Neugebauer V. Block of NMDA and non-NMDA receptor activation results
in reduced background and evoked activity of central amygdala neurons in a
model of arthritic pain. Pain 2004;110:112–22.
[8] Myers RD. Injection of solutions into cerebral tissue: relation between volume
and diffusion. Physiol Behav 1966;1:171–4.
[9] Neugebauer V. Subcortical processing of nociceptive information: basal ganglia
and amygdala. In: Cervero F, Jensen TS, editors. Handbook of clinical neurology,
vol. 81. Amsterdam: Elsevier; 2006. p. 141–58.
[10] Neugebauer V, Li W, Bird GC, Bhave G, Gereau IV RW. Synaptic plasticity in
the amygdala in a model of arthritic pain: differential roles of metabotropic
glutamate receptors 1 and 5. J Neurosci 2003;23:52–63.
[11] Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Aca-
demic Press; 1998.
[12] Pedersen LH, Scheel-Kruger J, Blackburn-Munro G. Amygdala GABA-A receptor
involvement in mediating sensory-discriminative and affective-motivational
pain responses in a rat model of peripheral nerve injury. Pain 2007;127:
17–26.
[13] Pertovaara A, Wei H. A dissociative change in the efﬁcacy of supraspinal versus
spinal morphine in the neuropathic rat. Pain 2003;101:237–50.
[14] Phelps EA, LeDoux JE. Contributions of the amygdala to emotion processing:
from animal models to human behavior. Neuron 2005;48:175–87.
[15] ViisanenH,PertovaaraA. Inﬂuenceofperipheralnerve injuryon responseprop-
erties of locus coeruleus neurons and coeruleospinal antinociception in the rat.
Neuroscience 2007;146:1785–94.
